Ashland

Q3 FY2026 EarningsQ3 FY26 revenue of $497M beat the $486M consensus by 2.27%, driven by strong volume growth in Life Sciences and Personal Care. However, Adjusted Diluted EPS of $0.75 missed the $0.98 consensus by 23.82%, primarily due to higher-than-expected unallocated corporate expenses and a 27% effective tax rate vs. 23.5% expected. Management reaffirmed full-year sales and Adjusted EBITDA guidance but lowered its Adjusted EPS growth outlook to low-to-mid-single digits, citing tax headwinds from discrete items.